Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

NCT02402764 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Selinexor

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]